DGAP-Adhoc: SHOP APOTHEKE EUROPE: ACQUISITION OF 'FIRST A', A PIONEERING QUICK-COMMERCE PLAYER IN THE GERMAN PHARMACY MARKET.
|
DGAP-Ad-hoc: SHOP APOTHEKE EUROPE N.V. / Key word(s): Takeover
SHOP APOTHEKE EUROPE: ACQUISITION OF 'FIRST A', A PIONEERING QUICK-COMMERCE PLAYER IN THE GERMAN PHARMACY MARKET.
12-Apr-2022 / 19:10 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
SHOP APOTHEKE EUROPE: ACQUISITION OF "FIRST A", A PIONEERING QUICK-COMMERCE PLAYER IN THE GERMAN PHARMACY MARKET.
- Strategic acquisition of one of Germany's pioneer in q-commerce that delivers pharmacy products door-to-door within 30 minutes.
- Entry into the growing q-commerce market.
- Complementing the launch of e-Rx through close partnerships with local pharmacies.
- Strategic acquisition accelerates SHOP APOTHEKE EUROPE's customer-centric platform strategy and strengthens its position as one stop shop in the pharmacy space.
Sevenum, the Netherlands, 12 April 2022. Today,SHOP APOTHEKE EUROPE acquired all shares of FIRST A. Founded as a start-up in Berlin in 2021, this company is now a leading quick-commerce delivery service in the pharmacy sector and offers medicine delivery within 30 minutes in five major German cities.
Today, SHOP APOTHEKE EUROPE acquired 100 % of the shares of FIRST A. All three founders and the current management team will stay on board and the company is expected to continue to operate stand-alone in order to lead and to manage the growth of FIRST A. The purchase price consists of an amount due at closing and conditional performance-related earn-outs on the basis of pre-agreed financial KPIs over the coming four years, which combined sum to an expected double-digit million amount.
Contact:
rikutis consulting
Thomas Schnorrenberg
Cel: +49 151 46 53 13 17
E-Mail: [email protected]
12-Apr-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
|
| Language: |
English |
| Company: |
SHOP APOTHEKE EUROPE N.V. |
|
Erik de Rodeweg 11-13 |
|
5975 WD Sevenum |
|
Netherlands |
| Phone: |
0800 - 200 800 300 |
| Fax: |
0800 - 90 70 90 20 |
| E-mail: |
[email protected] |
| Internet: |
www.shop-apotheke-europe.com |
| ISIN: |
NL0012044747, DE000A19Y072 |
| WKN: |
A2AR94, A19Y07 |
| Indices: |
SDAX |
| Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: |
1326777 |
| |
| End of Announcement |
DGAP News Service |
1326777 12-Apr-2022 CET/CEST
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
| Umsatzerlöse1 |
283,99 |
539,71 |
701,01 |
968,06 |
1.060,32 |
1.204,35 |
1.798,76 |
| EBITDA1,2 |
-12,14 |
-15,56 |
-18,58 |
15,20 |
-38,73 |
-29,66 |
39,99 |
| EBITDA-Marge3 |
-4,27 |
-2,88 |
-2,65 |
1,57 |
-3,65 |
-2,46 |
|
| EBIT1,4 |
-19,20 |
-28,73 |
-33,45 |
-0,87 |
-65,70 |
-69,17 |
-17,30 |
| EBIT-Marge5 |
-6,76 |
-5,32 |
-4,77 |
-0,09 |
-6,20 |
-5,74 |
-0,96 |
| Jahresüberschuss1 |
-21,36 |
-33,61 |
-36,27 |
-16,77 |
-74,19 |
-77,65 |
-11,61 |
| Netto-Marge6 |
-7,52 |
-6,23 |
-5,17 |
-1,73 |
-7,00 |
-6,45 |
-0,65 |
| Cashflow1,7 |
-23,24 |
-23,54 |
-30,37 |
17,80 |
11,64 |
-29,11 |
61,46 |
| Ergebnis je Aktie8 |
-2,25 |
-2,79 |
-2,78 |
-1,17 |
-4,15 |
-4,32 |
-0,73 |
| Dividende8 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Mazars
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| Redcare Pharmacy |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| A2AR94 |
135,400 |
Halten |
2.754,37 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 75,22 |
0,00 |
0,00 |
-64,85 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 5,27 |
44,82 |
1,53 |
72,98 |
| Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e
in % |
Hauptversammlung |
| 0,00 |
0,00 |
0,00 |
17.04.2024 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
| 25.04.2024 |
30.07.2024 |
05.11.2024 |
05.03.2024 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| -2,62% |
10,98% |
3,36% |
53,79% |
|
|
SHOP APOTHEKE EUROPE N.V. NL0012044747